RXRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Recursion Pharmaceuticals Inc (RXRX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive partnerships and revenue growth, the financial performance is weak, technical indicators are neutral, and the stock shows a high probability of short-term declines. Additionally, there are no strong proprietary trading signals or significant insider or hedge fund activity to support a buy decision.
The MACD is positive but contracting, RSI is neutral at 47.021, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 3.572, with resistance at 3.828 and support at 3.316. Overall, technical indicators suggest a neutral trend.
Expanded partnership with Citeline to enhance AI-driven drug discovery.
Strong partnerships with major pharmaceutical companies like Roche, Merck, Bayer, and Sanofi.
Substantial milestone payments received in 2025, with potential for future payments exceeding $300 million.
Analysts have lowered the price target to $6 from $7, citing revised estimates and delayed REC-617 launch timing.
Weak financial performance with declining net income, EPS, and gross margin.
Stock trend analysis indicates a high probability of short-term declines (-0.86% next day, -2.16% next week, -8.9% next month).
In 2025/Q4, revenue increased significantly by 681.74% YoY to $35.54 million. However, net income dropped by -39.56% YoY to -$108.12 million, EPS declined by -60.38% YoY to -0.21, and gross margin fell by -132.98% YoY to 59.83%. The financials indicate strong revenue growth but poor profitability and margin performance.
BofA lowered the price target to $6 from $7 and maintained a Neutral rating, citing revised estimates, increased operating expenses, and delayed REC-617 launch timing.
